Autologous tumor lysate (ATL)

Autologous tumor lysate is a personalized therapeutic substrate derived from the lysis of a patient's own surgically resected tumor cells. Rather than targeting a single protein, it provides a comprehensive library of tumor-associated antigens (TAAs) and patient-specific neoantigens that reflect the unique molecular signature and heterogeneity of an individual's cancer (National Cancer Institute Drug Dictionary). This approach is primarily utilized in the production of personalized cancer vaccines, such as dendritic cell vaccines, where the lysate is used to 'train' the patient's immune system to recognize and attack malignant cells. By presenting a broad spectrum of antigens, autologous tumor lysate aims to overcome the challenge of 'antigen escape,' a common mechanism of resistance where tumors downregulate specific targets to evade immune detection (Srivatsan, S., et al. 2014, Methods in Molecular Biology). While highly specific to the patient, its use is limited by the requirement for sufficient high-quality tumor tissue and the logistical complexities of individualized manufacturing.

Other names

Patient-specific tumor lysateWhole tumor lysateAutologous tumor cell lysateTumor-derived lysate

Autologous tumor lysate acts as a source of diverse antigens that are loaded into antigen-presenting cells (typically dendritic cells). These cells process the lysate and present tumor-specific peptides via MHC class I and II molecules to T-cells, inducing a polyclonal immune response against the patient's specific tumor profile (Liau, L. M., et al. 2023, JAMA Oncology).